INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY & FOR ACTIVE PSORIATIC ARTHRITIS ALONE OR IN COMBINATION WITH METHOTREXATE.
ADMINISTERED BY SUBCUTANEOUS INJECTION. IT IS RECOMMENDED THAT EACH INJECTION BE ADMINISTERED AT A DIFFERENT ANATOMIC LOCATION
PSORIASIS
* PATIENTS WEIGHING 100 KG OR LESS, DOSE IS 45 MG INITIALLY AND 4 WEEKS LATER, FOLLOWED BY 45 MG EVERY 12 WEEKS.
* PATIENTS WEIGHING > 100 KG (220 LBS), DOSE IS 90 MG INITIALLY AND 4 WEEKS LATER, FOLLOWED BY 90 MG EVERY 12 WEEKS.
* IN SUBJECTS WEIGHING > 100 KG, 45 MG WAS ALSO SHOWN TO BE EFFICACIOUS. HOWEVER, 90 MG RESULTED IN GREATER EFFICACY.
PSORIATIC ARTHRITIS
* RECOMMENDED DOSE IS 45 MG INITIALLY AND 4 WEEKS LATER, FOLLOWED BY 45 MG EVERY 12 WEEKS.
* FOR PATIENTS WITH CO-EXISTENT MODERATE-TO-SEVERE PLAQUE PSORIASIS WEIGHING > 100 KG (220 LBS), RECOMMENDED DOSE IS 90 MG INITIALLY AND 4 WEEKS LATER, FOLLOWED BY 90 MG EVERY 12 WEEKS.